NO893818L - Produksjon og anvendelse av hybride, monoklonale antistoffer. - Google Patents

Produksjon og anvendelse av hybride, monoklonale antistoffer.

Info

Publication number
NO893818L
NO893818L NO89893818A NO893818A NO893818L NO 893818 L NO893818 L NO 893818L NO 89893818 A NO89893818 A NO 89893818A NO 893818 A NO893818 A NO 893818A NO 893818 L NO893818 L NO 893818L
Authority
NO
Norway
Prior art keywords
hybrid
production
monoclonal antibodies
monoclonal
antibodies
Prior art date
Application number
NO89893818A
Other languages
English (en)
Other versions
NO893818D0 (no
Inventor
Susumu Iwasa
Tomofumi Kurokawa
Yukio Toyoda
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of NO893818D0 publication Critical patent/NO893818D0/no
Publication of NO893818L publication Critical patent/NO893818L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO89893818A 1988-09-27 1989-09-26 Produksjon og anvendelse av hybride, monoklonale antistoffer. NO893818L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP24354488 1988-09-27
JP30192588 1988-11-28
JP6294089 1989-03-14
JP16487389 1989-06-27
JP20893689A JP3177776B2 (ja) 1988-09-27 1989-08-11 ハイブリッドモノクローナル抗体，抗体産生ポリドーマおよび抗体含有薬剤

Publications (2)

Publication Number Publication Date
NO893818D0 NO893818D0 (no) 1989-09-26
NO893818L true NO893818L (no) 1990-03-28

Family

ID=27523741

Family Applications (1)

Application Number Title Priority Date Filing Date
NO89893818A NO893818L (no) 1988-09-27 1989-09-26 Produksjon og anvendelse av hybride, monoklonale antistoffer.

Country Status (15)

Country Link
US (1) US5506135A (no)
EP (1) EP0363712B1 (no)
JP (1) JP3177776B2 (no)
KR (1) KR900004351A (no)
CN (1) CN1041783A (no)
AR (1) AR242832A1 (no)
AT (1) ATE140930T1 (no)
AU (1) AU628857B2 (no)
DE (1) DE68926899T2 (no)
DK (1) DK474189A (no)
FI (1) FI894551A (no)
HU (1) HUT55445A (no)
IL (1) IL91649A (no)
NO (1) NO893818L (no)
PT (1) PT91808B (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068322A1 (en) * 1988-04-18 2003-04-10 Immunomedics, Inc. Methods of antibody-directed enzyme-prodrug therapy
TW212184B (no) * 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
JPH0576385A (ja) * 1990-12-18 1993-03-30 Takeda Chem Ind Ltd キメラ抗体およびその用途
WO1992019973A1 (en) * 1991-04-26 1992-11-12 Surface Active Limited Novel antibodies, and methods for their use
WO2015053381A1 (ja) * 2013-10-10 2015-04-16 幸成 加藤 抗ポドプラニン抗体
EP3620471A4 (en) * 2017-05-02 2021-01-06 National Cancer Center Japan ANTIBODY-ANTI-FIBRIN DRUG CONJUGATE INSOLUBLE, POSSIBLE TO BE CLIVID BY PLASMINE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4714681A (en) * 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
CA1213229A (en) * 1982-04-12 1986-10-28 Gary S. David Antibodies having dual specificities, their preparation and uses therefor
US4916070A (en) * 1986-04-14 1990-04-10 The General Hospital Corporation Fibrin-specific antibodies and method of screening for the antibodies
JP2635343B2 (ja) * 1986-04-14 1997-07-30 ザ・ジェネラル・ホスピタル・コーポレーション ヘテロ二官能性抗体および利用方法

Also Published As

Publication number Publication date
CN1041783A (zh) 1990-05-02
JP3177776B2 (ja) 2001-06-18
US5506135A (en) 1996-04-09
DK474189A (da) 1990-03-28
DE68926899T2 (de) 1997-01-02
AR242832A1 (es) 1993-05-31
PT91808A (pt) 1990-03-30
EP0363712B1 (en) 1996-07-31
KR900004351A (ko) 1990-04-12
PT91808B (pt) 1995-05-31
FI894551A (fi) 1990-03-28
FI894551A0 (fi) 1989-09-26
ATE140930T1 (de) 1996-08-15
DK474189D0 (da) 1989-09-26
EP0363712A3 (en) 1990-08-16
AU4174789A (en) 1990-04-05
EP0363712A2 (en) 1990-04-18
IL91649A (en) 1994-10-21
IL91649A0 (en) 1990-04-29
AU628857B2 (en) 1992-09-24
NO893818D0 (no) 1989-09-26
HUT55445A (en) 1991-05-28
JPH03103175A (ja) 1991-04-30
DE68926899D1 (de) 1996-09-05

Similar Documents

Publication Publication Date Title
DE3883899D1 (de) Geänderte antikörper.
DK101890D0 (da) Monoklonale antistoffer mod human interleukin-4 og hybridomaer, der producerer saadanne
DE68924026D1 (de) Biosensor und dessen herstellung.
DE3867379D1 (de) Turbolader.
DE3581578D1 (de) Antikoerper, herstellung und verwendung.
DE68914244D1 (de) Monoklonaler Antikörper.
DE3854502D1 (de) Gegen hiv-antigene spezifischer monoklonaler antikörper.
NO870770L (no) FremgangsmŸte for fremstilling av monoklonale antistoffer.
DE3785967D1 (de) Monoklonale antikoerper gegen c5a und des-arg74-c5a, ihre herstellung und ihre verwendung.
DE3885355D1 (de) Monoklonale Antikörper.
EP0131627A4 (en) SPECIFIC ANTIGENS OF THE CEA FAMILY (CARCINO-EMBRYONIC ANTIGEN), SPECIFIC ANTIBODIES OF THESE ANTIGENS AND THEIR METHODS OF USE.
DK169987D0 (da) Human tumor-associated antigen, ca-ou1
NO893818D0 (no) Produksjon og anvendelse av hybride, monoklonale antistoffer.
DE3888437D1 (de) Immobilisierte Antikörper.
DK717888A (da) Monoklonale antistoffer
DE3780256D1 (de) Anti-pci-monoklonaler antikoerper.
DE3888604D1 (de) Monoklonale Antikörper gegen Antithrombinbindende Substanz und seine Verwendungen.
NO882335L (no) Fremgangsmaate for fremstilling av 5-(omega-ammonio-acyloksy-metylen)-tetrahydrofuraner og -tetrahydrotiofener.
NO873488D0 (no) Monoklonale antistoffer.
DK8089D0 (da) Monoclonale antistoffer, deres fremstilling og anvendelse.
DK370089A (da) Anti-urokinase monoklonale antistoffer
NO892716D0 (no) Fremgangsmaate for fremstilling av proteiner.
ZA897023B (en) Hybrid monoclonal antibodies,their production and use
DE3882066D1 (de) Monoclonaler antikoerper gegen menschliches lungenadenokarzinom.
NO176614C (no) Monoklonalt antistoff og cellelinje som produserer antistoff